BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27742636)

  • 1. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Swaminathan S; Pasipanodya JG; Ramachandran G; Hemanth Kumar AK; Srivastava S; Deshpande D; Nuermberger E; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S63-S74. PubMed ID: 27742636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
    Guiastrennec B; Ramachandran G; Karlsson MO; Kumar AKH; Bhavani PK; Gangadevi NP; Swaminathan S; Gupta A; Dooley KE; Savic RM
    Clin Pharmacol Ther; 2018 Oct; 104(4):733-741. PubMed ID: 29247506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
    Pasipanodya JG; McIlleron H; Burger A; Wash PA; Smith P; Gumbo T
    J Infect Dis; 2013 Nov; 208(9):1464-73. PubMed ID: 23901086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Pasipanodya JG; Smythe W; Merle CS; Olliaro PL; Deshpande D; Magombedze G; McIlleron H; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S284-S292. PubMed ID: 30496458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
    Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
    Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
    Kwara A; Enimil A; Gillani FS; Yang H; Sarfo AM; Dompreh A; Ortsin A; Osei-Tutu L; Kwarteng Owusu S; Wiesner L; Norman J; Kurpewski J; Peloquin CA; Ansong D; Antwi S
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):356-365. PubMed ID: 26407268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.
    Yang H; Enimil A; Gillani FS; Antwi S; Dompreh A; Ortsin A; Adu Awhireng E; Owusu M; Wiesner L; Peloquin CA; Kwara A
    Pediatr Infect Dis J; 2018 Jan; 37(1):43-51. PubMed ID: 28719501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and predictors of mortality among children co-infected with tuberculosis and human immunodeficiency virus at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. A retrospective follow-up study.
    Atalell KA; Birhan Tebeje N; Ekubagewargies DT
    PLoS One; 2018; 13(5):e0197145. PubMed ID: 29787596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden of disease and risk factors for death among children treated for tuberculosis in Malawi.
    Flick RJ; Kim MH; Simon K; Munthali A; Hosseinipour MC; Rosenberg NE; Kazembe PN; Mpunga J; Ahmed S
    Int J Tuberc Lung Dis; 2016 Aug; 20(8):1046-54. PubMed ID: 27393538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
    Skevaki CL; Kafetzis DA
    Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.